VivoSeq
Other

Lidocaine

0

Pipeline Programs

11

Active Trials

2

Companies Involved

Lidocaine is an early-stage landscape with 0 programs across 2 companies. The most active players are Scilex Pharmaceuticals, Inc., ZARS Pharma Inc..

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

140

clinical trials

Completed93 · 66%
Unknown status17 · 12%
Terminated10 · 7%
Withdrawn8 · 6%
Not yet recruiting5 · 4%
Recruiting4 · 3%
Other3 · 2%

Trial Activity

140 trials

Adding Lidocaine to Custodiol Mixture
Recruiting·FFayoum University Hospital·Phase 4·NCT07205757·70 enrolled
Buffered Lidocaine in the Pediatric Dental Patient
Completed·GGeisinger Clinic·Phase 4·NCT04055116·64 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)